LifeMD (LFMD) Is Up 17.3% After Expanding Telehealth Access To Wegovy Oral Pill – What’s Changed?

Simply Wall St.01-09

In early January 2026, LifeMD announced it is now offering Novo Nordisk’s newly FDA-approved Wegovy (semaglutide) pill through its nationwide telehealth platform, expanding virtual access to an oral ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602039377?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345","is_english":true,"pubTime":"2026-01-09 21:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602039377","market":"hk","top_or_hot":-1,"title":"LifeMD (LFMD) Is Up 17.3% After Expanding Telehealth Access To Wegovy Oral Pill – What’s Changed?","media":"Simply Wall St.","content":"<div>\n<p>In early January 2026, LifeMD announced it is now offering Novo Nordisk’s newly FDA-approved Wegovy (semaglutide) pill through its nationwide telehealth platform, expanding virtual access to an oral ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-lfmd/lifemd/news/lifemd-lfmd-is-up-173-after-expanding-telehealth-access-to-w\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LifeMD (LFMD) Is Up 17.3% After Expanding Telehealth Access To Wegovy Oral Pill – What’s Changed?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLifeMD (LFMD) Is Up 17.3% After Expanding Telehealth Access To Wegovy Oral Pill – What’s Changed?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-09 21:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-lfmd/lifemd/news/lifemd-lfmd-is-up-173-after-expanding-telehealth-access-to-w><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In early January 2026, LifeMD announced it is now offering Novo Nordisk’s newly FDA-approved Wegovy (semaglutide) pill through its nationwide telehealth platform, expanding virtual access to an oral ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-lfmd/lifemd/news/lifemd-lfmd-is-up-173-after-expanding-telehealth-access-to-w\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LFMD","symbol_name":"LifeMD Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-lfmd/lifemd/news/lifemd-lfmd-is-up-173-after-expanding-telehealth-access-to-w","article_id":"2602039377","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-lfmd/lifemd/news/lifemd-lfmd-is-up-173-after-expanding-telehealth-access-to-w","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602039377","pubTimestamp":1767964948,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In early January 2026, LifeMD announced it is now offering Novo Nordisk’s newly FDA-approved Wegovy (semaglutide) pill through its nationwide telehealth platform, expanding virtual access to an oral GLP-1 option for chronic weight management and cardiovascular health at cash-pay prices starting from US$149 per month for eligible patients.\nThis move deepens LifeMD’s collaboration with Novo Nordisk and positions the company more firmly in the fast-growing obesity care segment by pairing...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LFMD":"LifeMD Inc.","BK4167":"医疗保健技术","BK4183":"个人用品"},"translate_title":"LifeMD(LFMD)在扩大Wegovy口服药丸的远程医疗覆盖范围后上涨17.3%-发生了什么变化？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LFMD":1.5},"content_text":"In early January 2026, LifeMD announced it is now offering Novo Nordisk’s newly FDA-approved Wegovy (semaglutide) pill through its nationwide telehealth platform, expanding virtual access to an oral GLP-1 option for chronic weight management and cardiovascular health at cash-pay prices starting from US$149 per month for eligible patients. This move deepens LifeMD’s collaboration with Novo Nordisk and positions the company more firmly in the fast-growing obesity care segment by pairing branded GLP-1 therapies with an end-to-end digital care model spanning virtual visits, diagnostics, and coordinated pharmacy fulfillment. We’ll now examine how LifeMD’s expanded access to the Wegovy oral pill could influence its investment narrative around telehealth-based obesity care. The latest GPUs need a type of rare earth metal called Terbium and there are only 39 companies in the world exploring or producing it. Find the list for free.AdvertisementLifeMD Investment Narrative RecapTo own LifeMD, you need to believe its telehealth model can convert rising interest in obesity and chronic care into durable, recurring revenue despite ongoing losses and sector competition. The Wegovy oral pill launch and new US$50,000,000 revolving credit facility both touch the near term: the pill can reinforce weight management as the key growth driver, while the facility itself does not materially change the biggest risk around customer acquisition costs and refund-driven margin pressure. The Citizens Bank revolving credit facility is the most relevant recent announcement here, as it gives LifeMD additional financial flexibility while it scales higher priced GLP 1 offerings like the Wegovy pill. With no initial draw and covenants tied to leverage and interest coverage, this facility sits in the background of the main catalyst, which remains LifeMD’s ability to expand telehealth obesity care without further stressing unit economics or deepening revenue concentration in a small set of verticals. Yet investors should also be aware that concentration in a few segments could become far more problematic if... Read the full narrative on LifeMD (it's free!)LifeMD's narrative projects $370.0 million revenue and $30.0 million earnings by 2028.Uncover how LifeMD's forecasts yield a $9.25 fair value, a 131% upside to its current price.Exploring Other PerspectivesLFMD 1-Year Stock Price Chart Eight fair value estimates from the Simply Wall St Community span roughly US$1.78 to US$43.85, underscoring how far apart individual views can be. When you set that against LifeMD’s reliance on a few key verticals and the importance of scaling telehealth obesity care profitably, it becomes clear why you may want to compare several perspectives before drawing conclusions.Explore 8 other fair value estimates on LifeMD - why the stock might be worth less than half the current price!Build Your Own LifeMD NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your LifeMD research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.Our free LifeMD research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate LifeMD's overall financial health at a glance.Want Some Alternatives?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:These 16 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.Trump has pledged to \"unleash\" American oil and gas and these 22 US stocks have developments that are poised to benefit.AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602039377","isCrawlerRequest":true}